Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-09-30 am EDT
3626.00 JPY   -0.11%
09/29Chugai Pharmaceutical : Files New Drug Application in Japan for Fixed-Dose Subcutaneous Combination of Pertuzumab and Trastuzumab for HER2-Positive Breast and Colorectal Cancer
PU
09/28Japan's Nikkei tracks Wall Street higher as Treasury yields fall
RE
09/09Japan's Nikkei ends week on a high in hawkish climate
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chugai Pharmaceutical : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoclonal Antibody Mitchga for the Treatment of Itching Associated with Atopic Dermatitis

08/07/2022 | 10:44pm EDT

Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoclonal Antibody Mitchga for the Treatment of

Itching Associated with Atopic Dermatitis

  • Maruho launched Mitchga, a novel antibody pharmaceutical originated by Chugai
  • Mitchga is the first antibody drug targeting IL-31 receptor A, for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective)

TOKYO, August 8, 2022 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Maruho Co., Ltd.(hereafter, Maruho) launched the anti-IL-31 receptor A humanized monoclonal antibody Mitchga® Subcutaneous Injection 60 mg Syringes [generic name: nemolizumab (genetical recombination)] for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective). Mitchga was approved by the Ministry of Health, Labour and Welfare (MHLW) on March 28, 2022 and listed on the national health insurance (NHI) reimbursement price list on May 25, 2022.

"We are very pleased that Mitchga, created by Chugai as the first antibody drug that inhibits IL-31 signaling, has been launched by Maruho in Japan," said Chugai's President and CEO Dr. Osamu Okuda. "Maruho and Chugai has been collaborating in the development of Mitchga under the license agreement for the Japanese market in September 2016. Maruho will provide information on Mitchga based on their extensive expertise in dermatology. We hope that Mitchga will contribute to improve the QOL of patients with atopic dermatitis by reducing itchiness."

[Reference information]

Maruho Launches the First Antibody Treatment Targeting Itch Associated with Atopic Dermatitis "Mitchga® Subcutaneous Injection 60mg Syringes" in Japan (Press release issued by Maruho on August 8, 2022)

https://www.maruho.co.jp/english/information/20220808.html

Maruho Obtained Regulatory Approval for Mitchga, the First Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis (Press release issued by Chugai on March 28, 2022) https://www.chugai-pharm.co.jp/english/news/detail/20220328160001_908.html

Results of Maruho's Phase III Study with Chugai's Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online (Press release issued by Chugai on July 9, 2020) https://www.chugai-pharm.co.jp/english/news/detail/20200709120000_726.html

About nemolizumab

Nemolizumab is an anti-IL-31 receptor A humanized monoclonal antibody originating from Chugai. The drug is expected to improve itching and skin inflammation in AD by blocking IL-31, a proinflammatory cytokine, from binding to its receptor 1).

In July 2016, Chugai entered into a global license agreement granting Galderma S.A. of Switzerland exclusive rights for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan. In September 2016, Chugai entered into a license agreement granting Maruho Co., Ltd., the rights for the development and marketing of nemolizumab in the skin disease area for the Japanese market. In development for AD, Galderma initiated global Phase III studies in 2019. In addition, nemolizumab was granted breakthrough therapy designation by the U.S. FDA for pruritus associated with prurigo nodularis (PN). Galderma launched a Phase III clinical study for the treatment of PN in October 2020, while Maruho, started Phase II/III clinical studies in Japan in December 2020.

About atopic dermatitis (AD)

A type of allergic disorder, AD is a chronic skin disease characterized by an itchy rash that alternately improves and worsens. Scratching the affected area exacerbates the skin symptoms and makes the itching worse, leading to an itch-scratch cycle. The basic treatment is drug therapy using topical steroid preparations and/or immunosuppressants to control the inflammation and a skin care regimen to prevent the inflammation from recurring 2). The prevalence of the disease in Japanese adults is estimated to be about 5.5 million 3).

Trademarks used or mentioned in this release are protected by law.

Sources

  1. Oyama S., et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp. Dermatol. 2018; 27(1): 14-21
  2. Japanese guidelines for atopic dermatitis 2021
  3. T Muto, et al. Prevalence of atopic dermatitis in Japanese adults. British Journal of Dermatology. 2003; Volume148, Issue1

###

2 / 2

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 02:43:05 UTC.


© Publicnow 2022
All news about CHUGAI PHARMACEUTICAL CO., LTD
09/29Chugai Pharmaceutical : Files New Drug Application in Japan for Fixed-Dose Subcutaneous Co..
PU
09/28Japan's Nikkei tracks Wall Street higher as Treasury yields fall
RE
09/09Japan's Nikkei ends week on a high in hawkish climate
RE
09/08Japanese stocks gain as investors digest cenbank decisions
RE
09/08Chugai Pharmaceutical : Summary
PU
08/24Roche's Japanese Unit Obtains Approval For Anticancer Medication
MT
08/24Chugai Pharmaceutical : Obtains Regulatory Approval for POLIVY for Additional Indication o..
PU
08/22Chugai Pharmaceutical : and Noile-Immune Biotech Enter into a License Agreement for Noile-..
PU
08/15Chugai Pharmaceutical : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl..
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
More news
Financials
Sales 2022 1 209 B 8 355 M 8 355 M
Net income 2022 360 B 2 487 M 2 487 M
Net cash 2022 529 B 3 653 M 3 653 M
P/E ratio 2022 16,7x
Yield 2022 2,19%
Capitalization 5 965 B 41 225 M 41 225 M
EV / Sales 2022 4,50x
EV / Sales 2023 4,99x
Nbr of Employees 7 664
Free-Float 38,0%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 626,00 JPY
Average target price 4 470,00 JPY
Spread / Average Target 23,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-2.92%41 225
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296